Literature DB >> 12020255

Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy.

David R Lynch1, Jennifer M Farmer, Laura J Balcer, Robert B Wilson.   

Abstract

The discovery of the genetic cause of Friedreich ataxia has significantly affected our understanding of the disorder at both the clinical and basic science levels. Friedreich ataxia results from a deficiency of functional frataxin, a protein that appears to be involved in mitochondrial iron homeostasis. This leads to iron accumulation and mitochondrial abnormalities with consequent oxidant damage. The clinical spectrum of Friedreich ataxia has also expanded with the recognition of broader phenotypic features, including the absence of classical Friedreich ataxia features, later age at onset, and spasticity instead of ataxia. Although no proven therapy is yet available, antioxidants are a potential method for therapeutic intervention.

Entities:  

Mesh:

Year:  2002        PMID: 12020255     DOI: 10.1001/archneur.59.5.743

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  33 in total

1.  A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype.

Authors:  Marguerite V Evans-Galea; Louise A Corben; Justin Hasell; Charles A Galea; Michael C Fahey; Desirée du Sart; Martin B Delatycki
Journal:  Neurogenetics       Date:  2011-08-10       Impact factor: 2.660

2.  Antioxidant use in Friedreich ataxia.

Authors:  Lauren Myers; Jennifer M Farmer; Robert B Wilson; Lisa Friedman; Amy Tsou; Susan L Perlman; Sub H Subramony; Christopher M Gomez; Tetsuo Ashizawa; George R Wilmot; Katherine D Mathews; Laura J Balcer; David R Lynch
Journal:  J Neurol Sci       Date:  2007-11-07       Impact factor: 3.181

3.  Mortality in Friedreich's Ataxia.

Authors:  David R Lynch; Jennifer M Farmer; Robert B Wilson
Journal:  Tex Heart Inst J       Date:  2007

4.  Genetic issues in the care of the adolescent patient.

Authors:  Lea Velsher
Journal:  Paediatr Child Health       Date:  2003-01       Impact factor: 2.253

5.  Utilisation of advance motor information is impaired in Friedreich ataxia.

Authors:  Louise A Corben; Martin B Delatycki; John L Bradshaw; Andrew J Churchyard; Nellie Georgiou-Karistianis
Journal:  Cerebellum       Date:  2011-12       Impact factor: 3.847

6.  A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia.

Authors:  Eric C Deutsch; Avni B Santani; Susan L Perlman; Jennifer M Farmer; Catherine A Stolle; Michael F Marusich; David R Lynch
Journal:  Mol Genet Metab       Date:  2010-07-08       Impact factor: 4.797

7.  Common data elements for clinical research in Friedreich's ataxia.

Authors:  David R Lynch; Massimo Pandolfo; Jorg B Schulz; Susan Perlman; Martin B Delatycki; R Mark Payne; Robert Shaddy; Kenneth H Fischbeck; Jennifer Farmer; Paul Kantor; Subha V Raman; Lisa Hunegs; Joanne Odenkirchen; Kristy Miller; Petra Kaufmann
Journal:  Mov Disord       Date:  2012-12-12       Impact factor: 10.338

8.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

9.  Impairment in motor reprogramming in Friedreich ataxia reflecting possible cerebellar dysfunction.

Authors:  Louise A Corben; Martin B Delatycki; John L Bradshaw; Malcolm K Horne; Michael C Fahey; Andrew J Churchyard; Nellie Georgiou-Karistianis
Journal:  J Neurol       Date:  2009-12-03       Impact factor: 4.849

10.  Analysis of the visual system in Friedreich ataxia.

Authors:  Lauren A Seyer; Kristin Galetta; James Wilson; Reiko Sakai; Susan Perlman; Katherine Mathews; George R Wilmot; Christopher M Gomez; Bernard Ravina; Theresa Zesiewicz; Khalaf O Bushara; S H Subramony; Tetsuo Ashizawa; Martin B Delatycki; Alicia Brocht; Laura J Balcer; David R Lynch
Journal:  J Neurol       Date:  2013-06-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.